Biovail Cardizem XL NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biovail submits NDA for the calcium channel blocker Cardizem XL Aug. 23 for treatment of hypertension. The once-daily, graded-release diltiazem formulation "uses a unique dissolution profile, in conjunction with nighttime dosing, to address the body's typical 24-hour circadian variation in blood pressure," the firm says. In Phase III trials comparing nighttime and daytime administration, evening use resulted in "statistically significant and clinically meaningful reductions in diastolic and systolic blood pressure" between 4 a.m. and 12 noon, "the time of day when patients are at the greatest risk of having an adverse cardiac event," the firm said. Biovail received approval in January 2000 for an earlier generation extended-release diltiazem without nighttime dosing. That formulation was never marketed
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.